Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival

por Dawson, S J, Duffy, S W, Blows, F M, Driver, K E, Provenzano, E, LeQuesne, J, Greenberg, D C, Pharoah, P, Caldas, C, Wishart, G C
Publicado 2009

The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape

por Modelska, A, Turro, E, Russell, R, Beaton, J, Sbarrato, T, Spriggs, K, Miller, J, Gräf, S, Provenzano, E, Blows, F, Pharoah, P, Caldas, C, Le Quesne, J
Publicado 2015

Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity

por Halliday, M, Radford, H, Sekine, Y, Moreno, J, Verity, N, le Quesne, J, Ortori, C A, Barrett, D A, Fromont, C, Fischer, P M, Harding, H P, Ron, D, Mallucci, G R
Publicado 2015

Resistance to HSP90 inhibition involving loss of MCL1 addiction

por Busacca, S, Law, E W P, Powley, I R, Proia, D A, Sequeira, M, Le Quesne, J, Klabatsa, A, Edwards, J M, Matchett, K B, Luo, J L, Pringle, J H, El-Tanani, M, MacFarlane, M, Fennell, D A
Publicado 2016

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

por Dawson, S-J, Makretsov, N, Blows, F M, Driver, K E, Provenzano, E, Le Quesne, J, Baglietto, L, Severi, G, Giles, G G, McLean, C A, Callagy, G, Green, A R, Ellis, I, Gelmon, K, Turashvili, G, Leung, S, Aparicio, S, Huntsman, D, Caldas, C, Pharoah, P
Publicado 2010

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

por Dawson, S-J, Makretsov, N, Blows, F M, Driver, K E, Provenzano, E, Le Quesne, J, Baglietto, L, Severi, G, Giles, G G, McLean, C A, Callagy, G, Green, A R, Ellis, I, Gelmon, K, Turashvili, G, Leung, S, Aparicio, S, Huntsman, D, Caldas, C, Pharoah, P
Publicado 2010